Epstein-Barr virus
Atara Biotherapeutics Seeking Approval for T-Cell Immunotherapy Tabelecleucel in US
The FDA is expected to decide whether to approve tabelecleucel as a treatment for EBV-positive post-transplant lymphoproliferative disease by Jan. 15, 2025.
Viracta Eyes FDA Accelerated Approval Path for Nana-val in EBV-Positive PTCL
The firm is advancing regulatory plans based on encouraging activity in refractory EBV-positive peripheral T-cell lymphoma in the NAVAL-1 trial.
Pierre Fabre Takes Over European Commercialization of Atara Biotherapeutics' Ebvallo
Atara will transfer Ebvallo's European marketing authorization for EBV-positive post-transplant lymphoproliferative disease, triggering a $30 million milestone payment.
Singapore Institutions Launch Program to Diagnose, Treat EBV-Associated Nasopharyngeal Cancer
The program, funded by Singapore's National Research Foundation, aims to identify Epstein-Barr virus strains associated with NPC in Southeast Asian populations.
Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
Pierre Fabre bought the EU commercialization rights to tabelecleucel, which Atara expects European regulators to approve for EBV-positive cancer this year.